9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment
AssigneeParatek Pharmaceuticals, Inc.
InventorsAmy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka, Judith N. Steenbergen, Stephen Bai
Life of this patent
Estimating the term…
Abstract
The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Claims22
A method of treating urinary tract infection (UTI) in a subject in need of treatment thereof, comprising administering to said subject:
- one intravenous (IV) loading dose, at the first day of treatment, of about 200 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof, and one or more oral maintenance doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof administered about 24 hours apart, wherein each of said one or more oral maintenance doses comprises about 300 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof,
- such that said subject is treated.
A method of treating urinary tract infection (UTI) in a subject in need of treatment thereof, comprising administering to said subject:
- two oral loading doses, at the first day of treatment, each about 300 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof, and one or more oral maintenance doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof administered about 24 hours apart, wherein each of said one or more oral maintenance doses comprises about 300 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof, such that said subject is treated.
A method of treating urinary tract infection (UTI) in a subject in need of treatment thereof, comprising administering to said subject:
- two oral loading doses, at the first day of treatment, each about 450 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof, and one or more oral maintenance doses of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof administered about 24 hours apart, wherein each of said one or more oral maintenance doses comprises about 450 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or salt thereof, such that said subject is treated.
Dependencies are inferred from the claim text.